Skip to main content
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. logo

SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. — Investor Relations & Filings

Ticker · 688163 ISIN · CNE1000059X8 LEI · 8368001TREMN2G5DDS70 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 335 across all filing types
Latest filing 2023-08-28 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688163

About SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.

https://www.serum-china.com.cn/en/

Shanghai Serum Bio-Technology Co., Ltd. is a specialized biopharmaceutical enterprise focused on the research, development, and manufacturing of therapeutic biological products. The company primarily produces a range of antiserums and antitoxins, including specialized antivenoms for various snake species, tetanus antitoxins, and rabies immunoglobulins. Its product portfolio supports emergency medical care and infectious disease management. The organization maintains advanced production facilities compliant with Good Manufacturing Practice (GMP) standards to ensure the safety and efficacy of its biological treatments. By leveraging biotechnological innovation, the company serves clinical needs in healthcare sectors, providing critical life-saving interventions for envenomation and acute bacterial toxins.

Recent filings

Filing Released Lang Actions
赛伦生物：关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanghai SAILUN Biotech Co., Ltd. regarding the delay of certain fundraising investment projects, specifically the factory expansion project. It details the original and revised timelines, reasons for the delay, and confirms that the delay does not affect the use of funds or harm shareholders' interests. The document includes opinions from the board, independent directors, and the sponsoring institution. It is a regulatory announcement about the status of capital investment projects and fundraising usage, not a full financial report or earnings release. The document length is about 3,138 characters, which is relatively short and focused on a specific announcement rather than a comprehensive report. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on the use and timing of fundraising projects.
2023-08-28 Chinese
赛伦生物：关于公司实际控制人之一、董事长被留置并立案调查的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the investigation and detention of the company's chairman and one of the actual controllers. It details changes in management responsibilities due to the chairman's inability to perform duties during the investigation. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. The content focuses on management and board changes due to legal issues. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2023-07-30 Chinese
赛伦生物：关于聘任高级管理人员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shanghai Sailun Biotechnology Co., Ltd. regarding the appointment of a senior management personnel, specifically the appointment of Mr. Peng Liangjun as Vice General Manager. It includes details about the appointment process, qualifications, and a biography of the appointee. There is no financial data, no mention of financial results, no regulatory filings or voting results, and no indication of other report types. The content clearly fits the category of Board/Management Information, which covers announcements of changes in the company's board of directors or senior management.
2023-07-05 Chinese
赛伦生物：独立董事关于第三届董事会第十三次会议相关事项的独立意见
Board/Management Information Classification · 100% confidence The document is an independent opinion from independent directors regarding the appointment of a company's deputy general manager, referencing compliance with company law, securities law, listing rules, and company articles. It discusses board meeting decisions and qualifications of the appointed executive. There is no financial data, no audit or financial report content, no earnings or capital update, and no shareholder voting results. The document relates to board/management information about a senior management appointment. The document length is short and it is not an announcement of a report publication but a formal opinion on management appointment. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-07-05 Chinese
赛伦生物：关于召开2022年度暨2023年第一季度业绩暨现金分红说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about an upcoming investor meeting scheduled for May 29, 2023, to discuss the company's 2022 annual results and 2023 first quarter performance, including cash dividends. It references that the 2022 annual report and 2023 first quarter report have already been published on April 21, 2023. The document provides details about the meeting time, location, participation method, and contact information. It does not contain actual financial statements or detailed financial data but serves as a notice for the investor presentation event. Therefore, this document is best classified as an Investor Presentation (IP) announcement rather than the report itself or a simple report publication announcement.
2023-05-22 Chinese
赛伦生物：2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution by Shanghai SAILUN Biotechnology Co., Ltd. It details the dividend per share, relevant dates (record date, ex-dividend date, payment date), tax treatment, and distribution methods. It references the approval of the dividend at the 2023 shareholders' meeting but does not contain financial statements or comprehensive financial data. The document is focused on dividend amount and payment details, which fits the definition of a Notice of Dividend Amount (DIV). The document length is short (2464 characters), and it is not a full annual report or earnings release. Therefore, the correct classification is Notice of Dividend Amount (DIV).
2023-05-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.